Evaluation of the Significance of Circulating Insulin-Like Growth Factor-1 and C-Reactive Protein in Patients with Chronic Obstructive Pulmonary Disease
Free accessResearch articleFirst published online June, 2012
Evaluation of the Significance of Circulating Insulin-Like Growth Factor-1 and C-Reactive Protein in Patients with Chronic Obstructive Pulmonary Disease
OBJECTIVES: This study in patients with chronic obstructive pulmonary disease (COPD) investigated whether acute exacerbation of COPD (AECOPD) and clinically stable COPD (CSCOPD) are associated with changes in circulating insulin-like growth factor-1 (IGF-1) and C-reactive protein (CRP) concentrations, and whether changes in IGF-1 and CRP levels are related to changes in the indicators of malnutrition and muscle wasting. METHODS: A total of 61 patients with AECOPD, 43 patients with CSCOPD and 20 healthy age-matched controls were included in the study. Circulating IGF-1 and CRP levels, together with erythrocyte sedimentation rate and indicators of malnutrition and muscle wasting, were measured in all the study participants. RESULTS: Circulating IGF-1 levels were significantly lower and CRP levels significantly higher in COPD patients than in controls. In addition, IGF-1 levels were significantly lower and CRP levels significantly higher in AECOPD patients than in CSCOPD patients. In COPD patients, indicators of malnutrition and muscle wasting (weight, body mass index, thigh circumference and albumin level) were significantly positively correlated with logIGF-1; thigh circumference and albumin level were significantly inversely correlated with logCRP. CONCLUSION: Circulating IGF-1 and CRP levels may have potential as indicators of exacerbation, malnutrition and muscle wasting in patients with COPD.
RabeKFHurdSAnzuetoA: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med2007; 176: 532–555.
2.
LaghiFAdiguzelNTobinMJ: Endocrinological derangements in COPD. Eur Respir J2009; 34: 975–996.
3.
SergiGCoinAMarinS: Body composition and resting energy expenditure in elderly male patients with chronic obstructive pulmonary disease. Respir Med2006; 100: 1918–1924.
4.
KoehlerFDoehnerWHoernigS: Anorexia in chronic obstructive pulmonary disease—association to cachexia and hormonal derangement. Int J Cardiol2007; 119: 83–89.
5.
KythreotisPKokkiniAAvgeropoulouS: Plasma leptin and insulin-like growth factor I levels during acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med2009; 9: 11.
6.
CoşkunFEgeEUzaslanE: Evaluation of thyroid hormone levels and somatomedin-C (IGF-1) in patients with chronic obstructive pulmonary disease (COPD) and relation with the severity of the disease. Tuberk Toraks2009; 57: 369–375.
7.
de TorresJPPinto-PlataVCasanovaC: C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest2008; 133: 1336–1343.
8.
CanoNJPichardCRothH: C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest2004; 126: 540–546.
9.
KaradagFKirdarSKarulAB: The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med2008; 19: 104–108.
10.
de TorresJPCordoba-LanusELópez-AguilarC: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J2006; 27: 902–907.
11.
Pinto-PlataVMMüllerovaHTosoJF: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax2006; 61: 23–28.
12.
World Health Organization: Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser1995; 854: 1–452.
13.
SpruitMAGosselinkRTroostersT: Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-1. Thorax2003; 58: 752–756.
14.
MohanSBaylinkDJ: IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol2002; 175: 19–31.
15.
DomenéHMBengoleaSVJasperHG: Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest2005; 28 (5 suppl): 43–46.
BroekhuizenRWoutersEFCreutzbergEC: Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax2006; 61: 17–22.
18.
SassoonCSZhuEPhamHT: Acute effects of high-dose methylprednisolone on diaphragm muscle function. Muscle Nerve2008; 38: 1161–1172.
19.
SharafkhanehAMattewalASAbrahamVM: Budesonide/formoterol combination in COPD: A US perspective. Int J Chron Obstruct Pulmon Dis2010; 5: 357–366.
20.
SinDDManSFMarciniukDD: The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med2008; 177: 1207–1214.
21.
TattersfieldAEHarrisonTWHubbardRB: Safety of inhaled corticosteroids. Proc Am Thorac Soc2004; 1: 171–175.
22.
SchuetzPChrist-CrainMSchildU: Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med2008; 8: 1.
23.
ShinSYLeeJRNohGW: Analysis of serum levels of anti-Mullerian hormone, inhibin B, insulin-like growth factor-I, insulinlike growth factor binding protein-3, and follicle-stimulating hormone with respect to age and menopausal status. J Korean Med Sci2008; 23: 104–110.
24.
VermeerenMACreutzbergECScholsAM: Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med2006; 100: 1349–1355.
25.
CrulTSpruitMAGayan-RamirezG: Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest2007; 37: 897–904.
26.
ManSFConnettJEAnthonisenNR: C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax2006; 61: 849–853.
27.
Piehl-AulinKJonesILindvallB: Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration2009; 78: 191–196.
28.
HurstJRDonaldsonGCPereraWR: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med2006; 174: 867–874.
29.
SinDDLacyPYorkE: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med2004; 170: 760–765.
30.
MaltaisF: Skeletal muscles in chronic airflow obstruction: why bother?Am J Respir Crit Care Med2003; 168: 916–917.
31.
OudijkEJNijhuisEHZwankMD: Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax2005; 60: 538–544.
SeemungalTADonaldsonGCBhowmikA: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med2000; 161: 1608–1613.
